- Home
- GNSS vs QNCX Comparison
GNSS vs QNCX Comparison
Compare GNSS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNSS
- QNCX
- Stock Information
- Founded
- GNSS 1992
- QNCX 2012
- Country
- GNSS United States
- QNCX United States
- Employees
- GNSS N/A
- QNCX N/A
- Industry
- GNSS Consumer Electronics/Appliances
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNSS Consumer Staples
- QNCX Health Care
- Exchange
- GNSS Nasdaq
- QNCX Nasdaq
- Market Cap
- GNSS 94.8M
- QNCX 85.9M
- IPO Year
- GNSS N/A
- QNCX 2019
- Fundamental
- Price
- GNSS $2.58
- QNCX $1.63
- Analyst Decision
- GNSS Strong Buy
- QNCX Strong Buy
- Analyst Count
- GNSS 3
- QNCX 6
- Target Price
- GNSS $5.33
- QNCX $8.00
- AVG Volume (30 Days)
- GNSS 133.0K
- QNCX 137.7K
- Earning Date
- GNSS 08-14-2025
- QNCX 11-12-2025
- Dividend Yield
- GNSS N/A
- QNCX N/A
- EPS Growth
- GNSS N/A
- QNCX N/A
- EPS
- GNSS N/A
- QNCX N/A
- Revenue
- GNSS $30,470,000.00
- QNCX N/A
- Revenue This Year
- GNSS $90.97
- QNCX N/A
- Revenue Next Year
- GNSS $75.75
- QNCX N/A
- P/E Ratio
- GNSS N/A
- QNCX N/A
- Revenue Growth
- GNSS 8.95
- QNCX N/A
- 52 Week Low
- GNSS $1.46
- QNCX $0.69
- 52 Week High
- GNSS $4.04
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- GNSS 82.16
- QNCX 49.14
- Support Level
- GNSS $2.08
- QNCX $1.56
- Resistance Level
- GNSS $2.17
- QNCX $1.67
- Average True Range (ATR)
- GNSS 0.13
- QNCX 0.07
- MACD
- GNSS 0.05
- QNCX 0.00
- Stochastic Oscillator
- GNSS 86.05
- QNCX 69.70
About GNSS Genasys Inc.
Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.